Application of circulating tumor DNA liquid biopsy in nasopharyngeal carcinoma:A case report and review of literature  

作　　者：Xin-Yao Zhou Yuan-Jun Jiang Xiao-Ming Guo Dong-Hui Han Yao Liu Qiao Qiao 

机构地区：[1]Department of Radiation Oncology,The First Hospital of China Medical University,Shenyang 110001,Liaoning Province,China [2]Department of Urology,The First Hospital of China Medical University,Shenyang 110001,Liaoning Province,China [3]Department of Artificial Intelligence and Algorithm R and D,Neusoft IntelliRay Technology,Shenyang 110000,Liaoning Province,China

出　　处：《World Journal of Clinical Cases》2025年第21期93-103,共11页世界临床病例杂志(英文)

基　　金：Supported by Beijing Bethune Charitable Foundation and Provincial Natural Science Foundation of Liaoning,No.2022-MS-190.

摘　　要：BACKGROUND Circulating tumor DNA(ctDNA)-based liquid biopsy has been found to be effective for the detection of minimal residual disease and the evaluation of prognostic risk in various solid tumors,with good sensitivity and specificity for identifying patients at high risk of recurrence.However,use of its results as a biomarker for guiding the treatment and predicting the prognosis of naso-pharyngeal carcinoma(NPC)has not been reported.CASE SUMMARY In this case study of a patient with stage IVb NPC,we utilized ctDNA as an independent biomarker to guide treatment.Chemotherapy was administered in the early stages of the disease,and local intensity-modulated radiation therapy was added when the patient tested positive for ctDNA,while radiation therapy was stopped and the patient was observed when the ctDNA test was negative.During the follow-up period,ctDNA signals became positive before tumor progression and became negative again at the end of treatment.We also explored the potential of ctDNA in combination with Epstein-Barr virus(EBV)DNA status to predict the prognosis of NPC patients,as well as the criteria for selecting genetic mutations and the testing cycle for ctDNA analysis.CONCLUSION The results of ctDNA-based liquid biopsy can serve as an independent biomarker,either independently or in conjunction with EBV DNA status,to guide the treatment and predict the prognosis of NPC.

关 键 词：Nasopharyngeal cancer Radiation therapy Circulating tumor DNA Epstein–Barr virus Minor residual disease Guide treatment Predicting prognosis Case report 

分 类 号：R739.63[医药卫生—肿瘤]